Mostrando 10 resultados de: 33
Filtros aplicados
Publisher
Journal of Nanobiotechnology(3)
Molecular Neurobiology(3)
Frontiers in Aging Neuroscience(2)
Nanomaterials(2)
Nanomedicine: Nanotechnology, Biology, and Medicine(2)
Área temáticas
Farmacología y terapéutica(24)
Enfermedades(22)
Medicina y salud(12)
Fisiología humana(7)
Ginecología, obstetricia, pediatría, geriatría(4)
Área de conocimiento
Farmacología(12)
Neurología(8)
Biotecnología(7)
Nanopartícula(7)
Ciencia de materiales(4)
Objetivos de Desarrollo Sostenible
ODS 9: Industria, innovación e infraestructura(28)
ODS 10: Reducción de las desigualdades(21)
ODS 12: Producción y consumo responsables(9)
ODS 2: Hambre cero(6)
ODS 17: Alianzas para lograr los objetivos(1)
Origen
scopus(33)
A metabolic perspective of late onset Alzheimer's disease
ReviewAbstract: After decades of research, the molecular neuropathology of Alzheimer's disease (AD)is still one of tPalabras claves:Alzheimer's disease, c-Jun N-terminal kinase inhibitors, Insulin, Licochalcone A, neuroinflammation, Reticulum stress, Type 2 Diabetes mellitusAutores:Antoni Camins, Auladell C., Busquets O., Cano A., Castro-Torres R.D., Ettcheto M., Folch J., García M.L., Manzine P.R., Olloquequi J., Sanchez-Lopez E., Verdaguer E., Zárate C.B.Fuentes:scopusComparative study of Ex Vivo transmucosal permeation of pioglitazone nanoparticles for the treatment of Alzheimer's disease
ArticleAbstract: Pioglitazone has been reported in the literature to have a substantial role in the improvement of ovPalabras claves:Alzheimer's disease, Nanoparticles, Pioglitazone, PLGA-PEG, Transmucosal permeationsAutores:Calpena A.C., Espina M., García M.L., Halbaut L., Lupe Carolina Espinoza, Silva-Abreu M.Fuentes:scopusBenzodiazepines and Related Drugs as a Risk Factor in Alzheimer's Disease Dementia
ArticleAbstract: Benzodiazepines (BZDs) and Z-drugs are compounds widely prescribed in medical practice due to theirPalabras claves:Alzheimer's disease, benzodiazepines, COGNITION, dementia, RISK FACTORSAutores:Antoni Camins, Auladell C., Bulló M., Busquets O., Cano A., Castro-Torres R.D., Ettcheto M., Folch J., García M.L., Manzine P.R., Olloquequi J., Sanchez-Lopez E., Zárate C.B.Fuentes:scopusBiodegradable nanoparticles for the treatment of epilepsy: From current advances to future challenges
ReviewAbstract: Epilepsy is the second most prevalent neurological disease worldwide. It is mainly characterized byPalabras claves:Epilepsy, lipid nanoparticles, Nanomedicine, nanotechnology, neurodegenerative diseases, Polymeric nanoparticlesAutores:Antoni Camins, Bonilla L., Cano A., Espina M., Esteruelas G., Ettcheto M., García M.L., Sanchez-Lopez E., Souto E.M.B.Fuentes:scopusCorrection to: Peripheral and Central Effects of Memantine in a Mixed Preclinical Mice Model of Obesity and Familial Alzheimer’s Disease (Molecular Neurobiology, (2018), 55, 9, (7327-7339), 10.1007/s12035-018-0868-4)
OtherAbstract: The original version of this article unfortunately contained mistake. The authors found that Fig. 4.Palabras claves:Autores:Antoni Camins, Auladell C., Busquets O., Cabrera H., Carrera M.V., Carro E., Casadesús G., Ettcheto M., Folch J., García M.L., Gómez-Mínguez Y., Sanchez-Lopez E., Zárate C.B.Fuentes:scopusArticle dexibuprofen biodegradable nanoparticles: One step closer towards a better ocular interaction study
ArticleAbstract: Ocular inflammation is one of the most prevalent diseases in ophthalmology, which can affect variousPalabras claves:Dexibuprofen, Drug delivery system, Nanoparticles, PLGAAutores:Alsafi Z., Antoni Camins, Calpena A.C., Cano A., Espina M., Esteruelas G., Ettcheto M., García M.L., Muñoz M., Ortiz A., Prat J., Pujol M., Sanchez-Lopez E., Souto E.M.B.Fuentes:scopusDual-drug loaded nanoparticles of Epigallocatechin-3-gallate (EGCG)/Ascorbic acid enhance therapeutic efficacy of EGCG in a APPswe/PS1dE9 Alzheimer's disease mice model
ArticleAbstract: Epigallocatechin-3-gallate (EGCG) is a candidate for treatment of Alzheimer's disease (AD) but its iPalabras claves:Alzheimer's disease, APP/PS1 mice, EGCG, Epigallocatechin gallate, PLGA-PEG, Polymeric nanoparticlesAutores:Antoni Camins, Auladell C., Barenys M., Barroso E., Cano A., Chang J.H., Espina M., Ettcheto M., Folch J., García M.L., Kühne B.A., Souto E.M.B., Turowski P.Fuentes:scopusDevelopment of Peptide Targeted PLGA-PEGylated Nanoparticles Loading Licochalcone-A for Ocular Inflammation
ArticleAbstract: Licochalcone-A is a natural compound with anti-inflammatory properties. However, it possesses low waPalabras claves:cell-penetrating peptides, Licochalcone-A, Nanoparticles, Ocular inflammation, PLGAAutores:Antoni Camins, Cano A., Espina M., Ettcheto M., Galindo R., García M.L., Gómara M.J., Haro I., Sanchez-Lopez E.Fuentes:scopusDevelopment of a nasal donepezil-loaded microemulsion for the treatment of Alzheimer’s disease: In vitro and Ex vivo characterization
ArticleAbstract: Background: Donepezil (DPZ) is widely prescribed as a specific and reversible acetylcholinesterase iPalabras claves:Alzheimer’s disease, Delivery systems, Donepezil, Intranasal route, Microemulsion, permeationAutores:Calpena A.C., Clares-Naveros B., Fábrega M.J., García M.L., Lupe Carolina Espinoza, Vacacela M.Fuentes:scopusDexibuprofen prevents neurodegeneration and cognitive decline in APPswe/PS1dE9 through multiple signaling pathways
ArticleAbstract: The aim of the present study is to elucidate the neuronal pathways associated to NSAIDs causing a rePalabras claves:Alzheimer's disease, APPswe/PS1dE9, Dexibuprofen, hippocampus, insulin receptor, Memory impairment, Mitochondria, TauAutores:Antoni Camins, Auladell C., Busquets O., Ettcheto M., Folch J., García M.L., Olloquequi J., Pallás M., Pons L., Sanchez-Lopez E., Zárate C.B.Fuentes:scopus